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Background: For patients with treatment-naïve carcinoma of the prostate, hypofractionated irradiation becomes
more and more popular. Due to the low α/β value of prostate cancer, increased single dose leading to a shortened
treatment period seems to be safe and feasible. However, reliable data is lacking for post-prostatectomy patients so
far. Further, the role of proton therapy is still under debate. Two prospective phase II trials with both,
hypofractionated photon and proton therapy, provided promising results.
Methods/ design: The PAROS trial is a prospective, multicenter and randomized phase III trial for men with
localized prostate carcinoma after surgery. Post-prostatectomy patients will be randomized to either
normofractionated radiotherapy (nRT) with photons (70.0/ 2.0 Gy), or hypofractionated radiotherapy (hRT) with
photons (57.0/ 3.0 Gy) or hRT with protons (57.0/ 3.0 Gy relative biological effectiveness [RBE]). Block randomization
is stratified by Gleason Score (≤ 7 vs. > 7) and treatment indication (adjuvant vs. salvage). The trial is planned to
enroll 897 patients. The primary objective is to show an improvement in the bowel-score according to EORTC QLQ-
PR25 after proton therapy compared to photon irradiation (week 12 vs. baseline). Secondary aims are non-inferiority
of hRT compared to nRT with regard to biochemical progression-free survival (bPFS), overall survival (OS), quality of
life and toxicity.
Discussion: The present study aims to evaluate the role of hypofractionated radiotherapy to the prostate bed with
photons and protons leading to significant impact on future management of operated men with prostate cancer.
Trial registration: Deutsches Register klinischer Studien: DRKS00015231; registered 27 September 2018.
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For patients with non-metastatic prostate carcinoma,
surgery or radiotherapy with or without hormonal ther-
apy (HT) are curative treatment options. After prosta-
tectomy, irradiation can be performed as adjuvant
therapy or after prostate specific antigen (PSA) rise.
While several larger studies reported on the oncological© The Author(s). 2019 Open Access This artic
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one prospective phase III trial evaluating the role of
dose-escalated salvage irradiation so far [3]. One multi-
center, prospective phase II study from Germany is cur-
rently analyzing the role of moderately dose-escalated
salvage radiotherapy in combination with local hyper-
thermia [4].
For some years now, hypofractionated irradiation be-
comes more and more common for patients with pros-
tate cancer. Many trials observed excellent clinical
outcome after moderate hypofractionation for patients
undergoing definitive radiotherapy [5–8]. As one of thele is distributed under the terms of the Creative Commons Attribution 4.0
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localized prostate cancer. With a median follow-up of
62.4 months, hypofractionated radiotherapy (hRT) with
60 Gy in 20 fractions was not inferior compared to con-
ventional fractionation. At 5 years, 90.6% in the 60 Gy
group and 88.3% in the 74 Gy group were free of bio-
chemical or clinical failure [5]. Nowadays, hypofractiona-
tion is frequently proclaimed as the “new standard of
care” for definitive radiotherapy of patients with prostate
cancer. However, in the postoperative setting reliable
data is missing with regard to hypofractionation. Few
studies with mostly small numbers of patients reported
on feasibility and toxicity. When using moderate hRT,
postoperative radiotherapy seems to be safe and pro-
vided promising clinical results [9–11]. Lewis et al. ob-
served no acute grade 3 toxicity and a 4-year bPFS of
75% in a cohort of 56 men. All patients obtained image-
guided intensity-modulated radiation therapy (IMRT) in
2.5 Gy fractions [12]. Our institution also tested different
approaches for hypofractionation after surgery: The
PRIAMOS 1 trial evaluated treatment safety and toxicity
of hRT of the prostate bed using IMRT and daily image-
guidance. In this prospective phase II trial, 40 men re-
ceived adjuvant or salvage irradiation with single doses
of 3.0 Gy up to a total dose of 54.0 Gy. Treatment was
tolerated well with no recorded side effects grade 3+
[13]. Very similar results were obtained when using pro-
ton therapy instead of photons. With the use of protons,
patient-reported bowel-score according to EORTC
QLQ-PR25 questionnaire was already improved at week
10 and reached borderline significance when compared
to photon therapy [data unpublished]. Therefore, larger
and randomized trials are of great interest evaluating the
role of hRT for patients after prostatectomy.
The PAROS trial is designed as a prospective,
multicenter and randomized 3-arm phase III trial
evaluating toxicity and efficacy of hypofractionation for
prostate cancer patients undergoing adjuvant or salvage
irradiation.Fig. 1 PAROS trial flowsheet. nRT = normofractionated radiotherapy;
hRT = hypofractionated radiotherapy; Gy = Gray; RBE = relative
biological effectivenessMethods
Primary and secondary endpoints
The primary endpoint is defined as the change in the
bowel-score according to EORTC QLQ-PR25 from base-
line to 12 weeks after start of proton therapy compared
to photon irradiation.
Secondary endpoints are bPFS after 5 years, quality of
life (QoL) according to EORTC QLQ-C30 and –PR25
after 2 and 5 years, clinical symptoms and toxicity ac-
cording to National Cancer Institute Common Termin-
ology Criteria for Adverse Effects (NCI CTCAE) version
5.0 after 2 and 5 years as well as overall survival (OS)
after 5 years.Trial design
The trial is a prospective, multicenter, randomized phase
III trial of patients with operated prostate carcinoma
and is planned to enroll 897 patients with localized pros-
tate cancer after prostatectomy. Patients will be random-
ized to one of the three arms: nRT with photons, hRT
with photons or hRT with protons. Total dose is 70.0 Gy
in 35 fractions for nRT with photons (arm 1), 57.0 Gy in
19 fractions for hRT with photons (arm 2) and 57.0 Gy
relative biological effectiveness (RBE) in 19 fractions for
hRT with protons (arm 3), respectively (Fig. 1). The
study was designed as a multicenter trial in at least
seven radio oncological centers in Germany and is con-
ducted in accordance with the Declaration of Helsinki
and the guidelines of Good Clinical Practice in their
current versions. Before trial initiation, the study was ap-
proved by the local institutional review board and the
expert committee of the German Society of Radiation
Oncology. Written informed consent will be obtained
from all patients prior to inclusion into the trial.
Inclusion and exclusion criteria
Inclusion criteria:
– histologically proven, localized prostate cancer with
classification according to Gleason Score/ WHO
grading and initial PSA value
– indication for adjuvant or salvage irradiation of the
prostate bed after prostatectomy
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imaging according to national guidelines for patients
with PSA persistence/ relapse and a PSA value of >
1 ng/ml
– Karnofsky index ≥70%
– age ≥ 18 years
– written informed consent
Exclusion criteria:
– hormonal therapy
– macroscopic tumor/ R2 resection margin
– nodal metastases
– distant metastases (M1)
– previous pelvic irradiation
– concurrent participation in other clinical trials,
which might influence the results of the present
study
– active medical implants without treatment approval
at the time of proton therapy (e.g. defibrillator,
pacemaker)
Pretreatment preparations/ randomization
When meeting the inclusion criteria, patients are in-
formed about the trial including potential risks and ben-
efits. After written informed consent, patients will be
allocated (1:1:1) in concealed fashion into one of the
three treatment arms (arms 1–3). Block randomization
will be carried out with permuted block sizes and strati-
fied by Gleason Score (GS) (≤ 7 vs. > 7) and treatment
indication (adjuvant vs. salvage) using a centralized web-
based tool (www.randomizer.at). Participating sites have
to register at the randomization platform before. All re-
quired documentation will be transferred to the study
center (Study Administration, Department of Radiation
Oncology, Heidelberg University Hospital, INF 400, 69,
120 Heidelberg).
Irradiation
Treatment planning and application will be performed
at the site of study enrollment. For centers without a
proton unit, patients randomized in arm 3 will be re-
ferred to one participating site with protons available.
Patient positioning and immobilization will be per-
formed according to institutional standards. Photon ir-
radiation will be applied in IMRT/ image-guided
radiotherapy (IGRT) technique, proton beam therapy is
performed as active beam application (raster scanning
method).
For contouring, the bladder, rectum, posterior third of
the rectum, bowel (small bowel, colon/ sigma) and
femoral heads will be defined as organs-at-risk (OAR).
Target volume delineation will be done according to
Radiation Therapy Oncology Group (RTOG) guidelines(post-OP prostate cancer). The planning target volume
(PTV) will be obtained by adding a 5 mm (anterior-
posterior; superior-inferior) and 7mm (lateral direction)
margin to the clinical target volume (CTV), respectively.
Total dose will be prescribed to 50% of the PTV for each
treatment arm. Equivalent dose in 2.0 Gy/ fraction (ED2)
for hRT (arm 2 + 3) is 69.7 Gy, calculated for 2.0 Gy
single dose considering an α/β value of 2.5. For proton
irradiation, dose will be calculated with an RBE of 1.1
according to ICRU 78.
Dose to OAR may not exceed the tolerance dose (TD)
5/5 (toxic dose leading to 5% severe complications over
5 years). The maximum dose of PTV_rectum (defined as
the intersection between PTV and the rectum) is 70.0
Gy (arm 1) and 57.0 Gy (RBE) (arm 2 + 3), respectively.
In the hRT arm, maximal EQD2 for the rectum is 66.5
Gy (RBE) (α/β value of 4).
Follow-up/ evaluation of efficacy and safety parameters
The first follow-up examination will be performed at 12
weeks after the start of irradiation. While regular uroon-
cological aftercare will be organized according to na-
tional guidelines, follow-up vists within the trial will be
scheduled after 6, 12, 24, 36 and 60 months (Table 1).
PSA levels can also be received from the treating urolo-
gist every 3months for the first 2 years and semi-
annually thereafter.
Acute and chronic toxicity will be evaluated according
to NCI CTCAE version 5.0 during and after the treat-
ment. EORTC QLQ-C30 and -PR25 questionnaires are
used to collect data on QoL.
Biochemical failure is defined as two consecutive in-
creases of PSA from nadir according to national guide-
lines [14–17]. bPFS is defined as time from first
diagnosis to biochemical failure. OS is defined as time
from the first diagnosis to death from any course. If the
respective event has been observed, the patient is cen-
sored at the date of the last follow-up examination.
Sample size calculation
The sample size calculation is based on the primary end-
point change in the bowel-score according to EORTC
QLQ-PR25 from baseline to 12 weeks. Based on numer-
ous trials, we assume a change of 6.5 points in the
standard arm (arm 1). Based on the two phase II trials
mentioned above, we assume a change of 6.5 points in
arm 2 as well and a change of 2.5 points in arm 3. Equal
standard deviation of 15 points is expected for all arms.
In the primary analysis, arm 1 will be compared with
arm 3 and arm 2 with arm 3. To control the overall type
I error of 5%, local significance levels of 2.5% according
to Bonferroni were applied in the sample size calcula-
tion. To achieve a power of 80% with the assumptions
above, a sample size of 269 per arm results for the two-
Table 1 Time schedule for the present trial
RT radiotherapy, PSA prostate specific antigen, CT computed tomography, QoL quality of life
*obtained from treating urologist or participating radio oncological center
grey = postal query or query by phone is permitted
Koerber et al. Radiation Oncology          (2019) 14:122 Page 4 of 6sided t-test. Calculations have been performed using
PASS 14.0.8. The primary analysis will be performed ap-
plying the Bonferroni Holm procedure and the factors
used in the stratified randomization will be considered.
This will lead to an increase in power. Based on the ex-
periences from previous studies, a conservative rate of
drop-outs and loss to follow-ups of 10% is expected. To
compensate for this loss in information, 299 patients per
arm are required resulting in a total of 897 patients to
be randomized.
Statistical analysis
In the primary analysis, arm 1 vs. arm 3 and arm 2 vs.
arm 3 will be compared regarding the primary endpoint
applying a linear regression model including the stratifi-
cation variables used in the randomisation procedure
and center. Primarily, the analysis will be based on the
Intention to treat population which consists of all ran-
domized patients treated at least for 1 week in the arm
as randomized. Missing values for the primary endpoint
will be imputed using multiple imputations under the
“missing at random” assumption and the results will be
pooled. To control the global type I error rate with 5%,the Bonferroni Holm procedure will be applied. In case
that at least one of the two comparisons can be consid-
ered significant, arm 1 vs. 2 will be compared at a sig-
nificance level of 5%, still controlling the global
significance level of 5%.
In addition, a complete case analysis will be carried
out. In the per protocol set only patients who were
treated as described in the protocol with complete docu-
mentation of relevant data will be considered. This set
will be analyzed as well as sensitivity analysis.
Time to event endpoints will be analyzed using Cox
proportional hazard models adjusting for the stratifica-
tion variables used in the randomization procedure. All
secondary endpoints will be descriptively analyzed using
statistical methods as appropriate for the underlying dis-
tribution of the data.
Safety endpoints will be analyzed based on the safety
population which comprises all patients who had at least
1 day of treatment, considered in the arm as treated.
Rates of acute and chronic toxicity will be calculated to-
gether with corresponding 95 confidence intervals for
group comparisons. Descriptive p-values for the chi-
squared test will be provided. Statistical methods will be
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treatment groups, endpoints and safety of the two inter-
vention groups. Details of the statistical analysis will be
fixed at the latest in the Statistical Analysis Plan (SAP)
to be prepared before database closure. This also in-
cludes the definition of the analysis populations.
Discussion
After prostatectomy, irradiation is recommended for
several patients with prostate cancer due to various cri-
teria like positive resection margins or PSA relapse. Al-
though prostate specific membrane antigen (PSMA)
positron emission tomography (PET)/CT is now avail-
able for recurrent disease, detection rates are limited; es-
pecially for low and very low PSA levels. Several studies
reported on a probability of about 50% in detecting
macroscopic tumor at PSA levels of < 0.5 ng/ml [18, 19].
Currently, there is no evidence for prolonging adjuvant
or salvage radiotherapy to reach higher detection rates
from PSMA PET/CT. Therefore, radiotherapy is often
prescribed to the prostate bed assuming this localization
has the highest risk for prostate cancer cells.
Today, nRT with photons is considered as the stand-
ard of care for patients undergoing irradiation after
prostatectomy. However, treatment time covers a period
of several weeks for each patient so far. Due to the low
α/β value of prostate cancer compared to relevant nor-
mal tissue, hypofractionation seems to be feasible and
safe without an increase of late reactions. However, in-
consistent data exist so far with regard to chronic side
effects: While several studies reported on similar late
toxicity when using postoperative, hRT [12, 20], Cozzar-
ini et al. observed a higher risk of late urinary toxicity in
a relatively small group of patients who underwent
hypofractionation. In this retrospective analysis, the 5-
year risk of severe (grade ≥ 3) late urinary side effects in-
creased in the heterogeneous cohort of patients treated
with different hRT regimes compared to men treated
with normofractionation [21]. Even though results
should be interpreted with caution due to the retrospect-
ive character of the study and the small number of
patients in the different hRT subgroups, additional re-
search is imperative.
Further, the role of post-prostatectomy proton therapy
is still unclear. Due to its physical characteristics, dose
to the target volume can be achieved more efficiently
with the use of particles like protons while leading to an
optimized sparing of the surrounding OAR. Apart from
previous in-house data, normofractionated proton
therapy is likely to be feasible and safe with a favorable
toxicity profile also in postoperative setting. Deville et al.
observed no acute and late adverse effects grade ≥ 3 in
a cohort of 100 men undergoing post-prostatectomy
nRT with a median follow-up of 25 months [22].Nevertheless, the potential reduction of side effects by
the use of protons is highly debated due to the fact, that
parts of the OAR are included in the target volume for
both, protons and photons. Prospective, randomized
trials are lacking so far.
The PAROS trial aims to evaluate the role of hypofrac-
tionated irradiation with either photons or protons for
patients with prostate carcinoma after surgery. The
study results will impact future management and treat-
ment recommendations for this large group of patients.
Trial status/ planned end of the study
Recruitment of the present trial was initiated in late
2018 and is expected to end in Q4 of 2023. The regular
end of study participation for each patient is 60 months
after the end of treatment (last patient out expected in
Q4 2028/ Q1 2029).
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